A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease (NCT05923073)

🧪 Interventions in This Study

• Guselkumab (DRUG)
• Guselkumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (85 Sites)

Showing the first 25 of 85 sites.

• Cedars Sinai Medical Center — Los Angeles, California
• Connecticut Children's Medical Center — Hartford, Connecticut
• Emory University — Atlanta, Georgia
• Children's Center for Digestive Health Care — Atlanta, Georgia
• Riley Hospital for Children — Indianapolis, Indiana
• Boston Childrens Hospital — Boston, Massachusetts
• Goryeb Children's Hospital — Morristown, New Jersey
• Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center — New York, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Columbia University Medical Center — New York, New York
• The Children's Medical Center of Dayton — Dayton, Ohio
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
• Cook Childrens Medical Center — Fort Worth, Texas
• University of Vermont Medical Center — Colchester, Vermont
• Perth Children's Hospital — Nedlands,
• Mater Hospital Brisbane — South Brisbane,
• The Children's Hospital at Westmead — Westmead,
• AKH - Medizinische Universitat Wien — Vienna,
• Universitair Ziekenhuis Brussel — Brussels,
• Cliniques Universitaires Saint Luc — Brussels,
• Universitair Ziekenhuis Gent — Ghent,
• UZ Leuven — Leuven,
• Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro — Campinas,
• Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro — Curitiba,
• Universidade Federal de Goias - Hospital das Clinicas da UFG — Goiânia,

📞 Contact the Study Coordinator

Phone: (844) 434-4210

Email: Participate-In-This-Study1@its.jnj.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Crohn's Disease

• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) — Birmingham, Alabama
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease — Birmingham, Alabama
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. — Sun City, Arizona
• Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. — Blacktown, New South Wales
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients — San Francisco, California
• Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis — Boston, Massachusetts

Explore by condition: All Crohn's Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.